Author:
Liu Qianqian,Li Wenzhang,Xue Miao,Chen Yunfeng,Du Xinmiao,Wang Chengdi,Han Lina,Tang Yin,Feng Yulin,Tao Chuanmin,He Jian-Qing
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. WHO. Global tuberculosis report 2015. Geneva, Switzerland: WHO, 2015.
http://www.who.int/tb/publications/global_report/en/
(accessed July 1, 2016).
2. Narayanan, P. R. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis. The Indian journal of tuberculosis 54, 84–90 (2007).
3. Ahuja, S. D. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS medicine 9, e1001300, doi:
10.1371/journal.pmed.1001300
(2012).
4. Faustini, A., Hall, A. J. & Perucci, C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61, 158–163, doi:
10.1136/thx.2005.045963
(2006).
5. Caminero, J. A. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 14, 382–390 (2010).
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献